Page 4 - Diagnostic Testing News Today

The demand for swift and accurate diagnosis of infectious diseases.

Cardiovascular Associates of America has added Daytona Heart Group, the largest cardiology care provider in Volusia County, FL, to its physician alliance.

An increase of COVID-19 instances and related symptoms is anticipated to fuel market growth. During the pandemic, telemedicine as well as remote monitoring use are projected to rise, increasing the demand for at-home diagnostic testing.Wilmington, Delaware, United States, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The COVID-19 diagnostics market was estimated to have acquired US$ 79.8 billion in 2021. It is anticipated to register a -7.9% CAGR from 2022 to 2031 and by

This endocrine case report from Brady Pregerson, MD, features a patients in his mid-70s with a history of hypothyroidism presenting with weeks of nausea, vomiting, and diarrhea without blood but with a 30-pound weight loss. Can you determine the most likely diagnosis?

Catherine Nester, RN, vice president of physician and patient strategies at Inozyme Pharma, highlights the importance of newborn screening for rare diseases and the impact of the BeginNGS diagnostic tool.

Pleural disease encompasses various conditions affecting the pleura, the thin membrane surrounding the lungs. Pleurisy involves inflammation of the pleura,...

Rise in incidence of the Lyme disease and growth in awareness about diagnostic tests are key Lyme disease diagnostics market drivers. The number of people affected with the Lyme disease is rising, particularly in regions with high prevalence of ticks.Wilmington, Delaware, United States, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global Lyme disease diagnostics market is expected to total US$ 1.56 billion in 2023 and is expected to expand at a CAGR of 3.8% until 203

Coverage of sessions on disparities in access to clinical trials and cancer screening, as well as relationships each to outcomes. A joint session presented by ASCO and the European Society for Medical Oncology (ESMO) highlighted progress and lingering gaps in lung and colorectal screening.

Biodesix, Inc. (NASDAQ:BDSX) Q2 2023 Earnings Call Transcript August 7, 2023 Biodesix, Inc. misses on earnings expectations. Reported EPS is $-0.17013 EPS, expectations were $0.21. Operator: Good day and thank you for standing by. Welcome to the Biodesix Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After […]

/PRNewswire/ -- The "United States Women Health Laboratory Testing Market by Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening...